Dexmedetomidine

Dexmedetomidine is a highly selective and potent α2-adrenergic receptor agonist widely used as a sedative, analgesic, and anxiolytic agent in both surgical and nonsurgical clinical settings. It exerts its primary effects by binding to α2-adrenergic receptors in the central and peripheral nervous system, producing dose-dependent sedation, analgesia, and sympatholysis without causing significant respiratory depression—a property that distinguishes it from many classical sedatives. Originally approved for intravenous use in intensive care and procedural sedation, dexmedetomidine has more recently been formulated in novel delivery formats including sublingual, nasal spray, and topical ophthalmic preparations, reflecting a broader expansion of its therapeutic applications. Its pharmacological profile also encompasses anti-inflammatory and neuroprotective properties, making it a subject of increasing interest beyond the perioperative setting.

Beyond sedation, dexmedetomidine has attracted significant attention for its neuroprotective effects in acute and chronic neurological conditions. Its ability to modulate neuroinflammation, support neuronal survival signaling, and interact with metabolic regulatory pathways such as AMPK/mTOR and Sirtuin 1 (SIRT1) (Sirt1) has positioned it as a candidate therapeutic agent in models of ischemic brain injury, neonatal hypoxic-ischemic encephalopathy, and neurodegenerative diseases including Alzheimer's disease (AD). These emerging mechanistic insights are driving a wave of preclinical and clinical research aimed at characterizing the full scope of dexmedetomidine's biological activity.